Vertex Reports Second Quarter 2025 Financial Results — Total revenue of $2.96 billion, a 12$11.85 to $12 billion — — Continued strong execution of CASGEVY , ALYFTREK and JOURNAVX launches — ® ® ® Second Quarter 2025 Results Total revenue increased 12$2.96 billion compared to the second quarter of 2024, primarily driven by the continued performance of cystic fibrosis (CF) therapies and early contr ...